热门资讯> 正文
Ultragenyx Pharmaceutical定价3.5亿美元证券发行
2024-06-14 16:45
- Ultragenyx Pharmaceutical (NASDAQ:RARE) announces the pricing of its underwritten public offering of 7,435,898 shares of its common stock at $39.00 per share, and pre-funded warrants offering to purchase 1,538,501 shares of its common stock at a purchase price of $38.999 per pre-funded warrant, for expected gross proceeds of $350 million.
- In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,346,153 shares of the company's common stock at the public offering price.
- The offering is expected to close on or about June 17, 2024.
More on Ultragenyx Pharmaceutical
- Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
- Ultragenyx to file for accelerated approval of rare metabolic disease candidate
- Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
- Seeking Alpha’s Quant Rating on Ultragenyx Pharmaceutical
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
